GlassScriptPhysician profile
Yuriy Gurevich
NPI 1336319680
$19,378.22
in general payments reported to CMS, 2019-2025
61 companies · $3,056 in 2025
The $3,056 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,956 · 2020: $1,690 · 2021: $2,878 · 2022: $2,764 · 2023: $3,330 · 2024: $2,703 · 2025: $3,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,027 · Education: $62.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,027.13 |
| Education | $62.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,476.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,756.30 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $1,552.17 | 2019-2025 | Evenity, Prolia, Tepezza |
| Corcept Therapeutics | $1,409.14 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $1,291.93 | 2019-2024 | Farxiga |
| Mannkind Corporation | $1,195.11 | 2019-2025 | Afrezza |
| Tandem Diabetes Care, INC. | $868.85 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $766.87 | 2019-2025 | Freestyle Libre |
| Sanofi-Aventis U.S. LLC | $742.57 | 2019-2025 | |
| Abbvie INC. | $725.94 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $712.44 | 2019-2025 | Jardiance |
| Antares Pharma, INC. | $607.15 | 2019-2025 | Xyosted |
| Pfizer INC. | $483.84 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $465.80 | 2021-2025 | |
| Insulet Corporation | $319.25 | 2019-2025 | Omnipod |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $304.26 | 2020-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $303.58 | 2019-2025 | Tymlos |
| Amneal Pharmaceuticals LLC | $303.00 | 2019-2025 | Unithroid |
| Ibsa Pharma INC. | $237.53 | 2019-2024 | Tirosint, Licart, Licart |
| Merck Sharp & Dohme LLC | $174.57 | 2019-2022 | |
| Ascendis Pharma Endocrinology INC | $165.70 | 2024-2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $156.66 | 2019-2025 | Strensiq |
| Amarin Pharma, INC. | $149.97 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $142.48 | 2022-2025 | Isturisa, Signifor Lar |
| Xeris Pharmaceuticals, INC. | $138.21 | 2023-2025 | Recorlev |
| Embecta Corp. | $133.43 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Madrigal Pharmaceuticals | $130.84 | 2025 | Rezdiffra |
| Endo Pharmaceuticals INC. | $128.90 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $119.23 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $104.10 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.68 | 2021-2022 | |
| Medtronic, INC. | $100.82 | 2021-2024 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Becton, Dickinson and Company | $86.09 | 2021-2022 | |
| Astellas Pharma US INC | $79.65 | 2023-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $69.42 | 2019-2020 | |
| Glaxosmithkline, LLC. | $67.01 | 2023-2024 | Shingrix, Arexvy |
| Ultragenyx Pharmaceutical INC. | $61.48 | 2021-2024 | Crysvita |
| Halozyme INC | $56.04 | 2023 | |
| Horizon Therapeutics Plc | $55.54 | 2022-2023 | Tepezza |
| Verity Pharmaceuticals INC. | $55.49 | 2024-2025 | Tlando |
| Ascensia Diabetes Care US INC. | $55.41 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $51.80 | 2025 | Imcivree |
| Azurity Pharmaceuticals, INC. | $46.69 | 2023 | Adthyza |
| Valeritas, INC. | $37.72 | 2019 | |
| Chiesi USA, INC. | $36.10 | 2024-2025 | Mycapssa |
| Alvogen INC | $36.08 | 2023-2024 | Teriparatide |
| Beta Bionics, INC. | $33.34 | 2024 | Ilet Bionic Pancreas |
| Lifescan, INC. | $33.08 | 2019 | |
| Vivus LLC | $30.64 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $23.85 | 2024 | |
| Clarus Therapeutics INC. | $21.44 | 2021 | |
| Intuity Medical INC | $20.17 | 2022 | |
| Exact Sciences Corporation | $19.92 | 2023 | Cologuard Collection Kit |
| Eusa Pharma (US) LLC | $19.91 | 2022 | |
| Cequr Corporation | $17.60 | 2025 | Cequr Simplicity |
| Rgh Enterprises LLC | $17.30 | 2024 | |
| Acerus Pharmaceuticals Corporation | $17.24 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.03 | 2022 | |
| Aytu Biopharma, INC. | $15.24 | 2019 | |
| Currax Pharmaceuticals LLC | $15.00 | 2020 | |
| Shire North American Group INC | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuriy Gurevich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.